Novavax shares closed at $7.37, down 1.6% in the latest trading session, underperforming the S&P 500's 0.21% gain. The vaccine maker's stock has fallen 19.98% over the past month, while the Medical sector lost 0.43% and the S&P 500 gained 1.7%. Analysts expect Novavax to report an EPS of negative $0.36 for the upcoming quarter, a 158.06% decline from the prior-year period, on projected revenue of $50.04 million, down 79.08%. For the full year, the Zacks Consensus Estimate anticipates an EPS of negative $0.19 and revenue of $371.85 million, representing declines of 107.36% and 66.9%, respectively. Despite these estimates, Novavax holds a Zacks Rank of 1, indicating a Strong Buy, and its industry, Medical - Biomedical and Genetics, ranks in the top 38% of over 250 industries.
Novavax IncAnalysts expect a 158% EPS decline and 79% revenue drop for the upcoming quarter.